Pfizer’s $6.9B Migraine Drug Buyout
Pfizer Buys Migraine Drug Maker for $6.9B In a bold move to dominate the neurology sector, Pfizer has agreed to acquire Revive Therapeutics, a leading migraine drug developer, for $6.9 billion. The keyword Pfizer to buy migraine drug maker for $6.9 billion highlights this blockbuster deal announced on September 22, 2025. As chronic migraine affects … Read more